-
[Interview] 'Eylea 8mg emerges as only nAMD therapy enabling 20-week dosing interval'
08 Dec 2025 05:06 GMT
… the Journal of Korean Medical Science, analyzing data … trial data to understand the advantages and characteristics of each drug … During treatment, second-generation anti-VEGF drugs, such as Eylea 8mg … anti-VEGF therapy clinical trials aim to demonstrate visual …
-
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
07 Dec 2025 21:30 GMT
… 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) … cancer, visit the clinical trials website, or contact via … LYNOZYFIC. Call your doctor for medical advice about side effects … into medicine has led to numerous approved treatments and …
-
<![CDATA[Celltrion’s EYLEA-referencing biosimilar, EYDENZELT, receives Canadian approval]]>
02 Dec 2025 23:02 GMT
… to Eylea, according to the trial data.
Additionally, study findings demonstrated both treatment … Food and Drug Administration (FDA) in October 2025.4 The FDA approval was … based on the same trial data as …
-
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?
01 Dec 2025 09:43 GMT
… Shares of Regeneron Pharmaceuticals (REGN 0.56%), a biotech giant, have … (HD) version of Eylea. HD Eylea doesn't have … main growth driver, eczema treatment Dupixent, for which it … trial results for others. In July, the FDA approved its Lynozyfic, a medicine …
-
Celltrion secures Health Canada go-ahead for Eylea biosimilar
28 Nov 2025 18:57 GMT
… of Pharmaceutical Technology.
To fend off the financial losses associated with Eylea … version of Eylea HD. The FDA rejected this formulation of the drug in … the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation …
-
Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)
28 Nov 2025 01:45 GMT
… to Eylea in patients with approved indications. The 52-week trial … from baseline, comparing Eydenzelt and Eylea. Results of the study … showed trends similar to Eylea.2 Eydenzelt is Celltrion’ … U.S. Food and Drug Administration (FDA) in February and October …
-
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
25 Nov 2025 06:00 GMT
… a “live vaccine” right before and during treatment with DUPIXENT. … DUPIXENT. Call your doctor for medical advice about side effects … of prescription drugs to the FDA. Visit www.fda.gov… future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or …
-
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
25 Nov 2025 06:00 GMT
… into medicine has led to numerous approved treatments and … system to invent medicines and vaccines that treat and … future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the … Product Candidates in clinical trials; determinations by regulatory …
-
Eylea Market to Reach $13.64 Billion by 2029 with 6.7% CAGR
24 Nov 2025 10:45 GMT
… drug delivery technologies, retinal imaging technologies, and clinical trials … , Regeneron Pharmaceuticals, Inc., a biotechnology company based … in the US known for their development of medicines … US FDA in August 2023 for Eylea HD …
-
Bayer shares jump on positive data from stroke drug trial
24 Nov 2025 13:25 GMT
… once-daily, 50-milligram treatment significantly reduced the risk … blood-thinning medicines.
It said the ‘OCEANIC-STROKE’ trial enrolled … The US Food and Drug Administration (FDA) has granted asundexian fast … on key drugs such as Xarelto and Eylea, as well …
About
© 1995-2025